cholesta-5,20-diene-3β-ol | 41083-90-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholesta-5,20-diene-3β-ol
• 英文别名: cholesta-5,20-dien-3β-ol；(3S,10R,13S,17R)-10,13-dimethyl-17-(6-methylhept-1-en-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol；Cholesta-5,20(21)-dien-3β-ol；Cholesta-5,20-dien-3-ol, (3beta)-；(3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-(6-methylhept-1-en-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 41083-90-3
• 化学式: C₂₇H₄₄O
• 分子量: 384.646
• InChiKey: UYTUOBVSKUYFBB-PKGHVVLQSA-N

物化性质

• 沸点：
  482.9±44.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3β-<(tetrahydro-2H-pyran-2-yl)oxy>-5-pregnen-20-one 在 碘 、 magnesium 、 甲基磺酰氯 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 cholesta-5,20-diene-3β-ol
  参考文献：
  名称：

  Glucal-conjugated sterols as novel vascular leakage blocker: Structure–activity relationship focusing on the C17-side chain

  摘要：

  A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C-17-side chain was also established. The sterol analogs linked with the rigid C-17-side chain side chains exhibited potent cell survival activities. In particular, analog 211, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.027

文献信息

• JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES
  申请人：Tao Weikang

  公开号：US20120157500A1

  公开（公告）日：2012-06-21

  The instant invention provides a method for treating patients by administering a JAK inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is a JAK2 inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is selected from selected from Jak2-IA, AG490, Pyridone 6, WP1066, LS104, TG101209, TG101348, CP690,550, CP352,664, INCB18424, WHI-P154, CMP6, SB1518, XL019, CEP-701, INCB20, AUH-6-96 and AZ960.
• Glucal-conjugated sterols as novel vascular leakage blocker: Structure–activity relationship focusing on the C17-side chain
  作者：Kyeojin Kim、Sony Maharjan、Changjin Lim、Nam-Jung Kim、Vijayendra Agrawal、Young Taek Han、Sujin Lee、Hongchan An、Hwayoung Yun、Hyun-Jung Choi、Young-Guen Kwon、Young-Ger Suh

  DOI：10.1016/j.ejmech.2014.01.027

  日期：2014.3

  A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C-17-side chain was also established. The sterol analogs linked with the rigid C-17-side chain side chains exhibited potent cell survival activities. In particular, analog 211, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model. (C) 2014 Elsevier Masson SAS. All rights reserved.